INDV FY 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

FY 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.2B+4.3% YoY

Gross Profit

$994M80.2% margin

Operating Income

$262M21.1% margin

Net Income

$210M16.9% margin

EPS (Diluted)

$1.64

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$93M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.3B

Stockholders' Equity

-$98M

Cash & Equivalents

$195M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.2B	$1.2B	+4.3%
Gross Profit	$994M	$957M	+3.9%
Operating Income	$262M	$32M	+718.8%
Net Income	$210M	$2M	+10400.0%